Context Therapeutics Inc. (NASDAQ:CNTX) Expected to Announce Earnings of -$0.24 Per Share

Brokerages expect Context Therapeutics Inc. (NASDAQ:CNTXGet Rating) to report ($0.24) earnings per share (EPS) for the current quarter, Zacks Investment Research reports. Zero analysts have provided estimates for Context Therapeutics’ earnings. The firm is scheduled to report its next earnings report on Monday, January 1st.

On average, analysts expect that Context Therapeutics will report full-year earnings of ($1.16) per share for the current fiscal year, with EPS estimates ranging from ($1.30) to ($1.01). For the next year, analysts anticipate that the company will report earnings of ($1.68) per share, with EPS estimates ranging from ($1.95) to ($1.40). Zacks Investment Research’s earnings per share averages are a mean average based on a survey of research analysts that follow Context Therapeutics.

Several brokerages have weighed in on CNTX. Zacks Investment Research upgraded Context Therapeutics from a “sell” rating to a “hold” rating in a report on Tuesday. HC Wainwright began coverage on Context Therapeutics in a report on Wednesday, February 2nd. They set a “buy” rating and a $6.00 price objective for the company. Finally, ThinkEquity began coverage on Context Therapeutics in a report on Monday, January 24th. They set a “buy” rating and a $10.00 price objective for the company.

Several institutional investors have recently modified their holdings of the company. BlackRock Inc. acquired a new stake in shares of Context Therapeutics in the 4th quarter valued at about $31,000. Virtu Financial LLC acquired a new stake in Context Therapeutics during the fourth quarter worth about $142,000. Altium Capital Management LP acquired a new stake in Context Therapeutics during the fourth quarter worth about $1,313,000. Renaissance Technologies LLC acquired a new stake in Context Therapeutics during the fourth quarter worth about $172,000. Finally, QCM Cayman Ltd. acquired a new stake in Context Therapeutics during the fourth quarter worth about $37,000. Institutional investors and hedge funds own 20.36% of the company’s stock.

NASDAQ:CNTX traded up $0.01 during midday trading on Monday, reaching $1.45. The company had a trading volume of 37,356 shares, compared to its average volume of 420,811. The business’s fifty day simple moving average is $1.96. Context Therapeutics has a 12-month low of $1.30 and a 12-month high of $10.87.

Context Therapeutics Company Profile (Get Rating)

Context Therapeutics Inc, a clinical-stage biopharmaceutical company, develops products for the treatment of cancer for women in the United States. Its lead product candidate is onapristone extended release (ONA-XR), a selective potent antagonist of the progesterone receptor that is linked to resistance for various classes of cancer therapeutics, such as ovarian, uterine (endometrial), and breast cancers.

Further Reading

Get a free copy of the Zacks research report on Context Therapeutics (CNTX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Context Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Context Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.